Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ANZCTR |
Last refreshed on:
|
11 June 2018 |
Main ID: |
ACTRN12617000789369 |
Date of registration:
|
30/05/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Triple therapy for new onset Type 2 Diabetes Mellitus (T2DM)
|
Scientific title:
|
A randomised controlled study aimed to normalise glycaemia using triple therapy in newly diagnosed patients with type 2 diabetes |
Date of first enrolment:
|
6/02/2017 |
Target sample size:
|
40 |
Recruitment status: |
Recruiting |
URL:
|
http://www.anzctr.org.au/ACTRN12617000789369.aspx |
Study type:
|
Interventional |
Study design:
|
Randomised controlled trial
Parallel |
Phase:
|
Phase 1
|
|
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
type 2 diabetes mellitus
|
Intervention(s)
|
Metformin XR - 7 days at 500mg followed by 7 days at 1000mg, followed by 7 days at 1500mg and then to a total daily dose of 2000mg for a duration of 12 months.
Saxagliptin - oral tablet at a total daily dose of 5mg for a duration of 12 months.
Dapagliflozin - oral tablet at a total daily dose of 10mg for a duration of 12 months.
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|